Advances in PET/CT Imaging for Breast Cancer

Jong, Dorine de; Desperito, Elise; Feghali, Karine A. Al; Dercle, Laurent; Seban, Romain-David; Das, Jeeban Paul; Ma, Hong; Sajan, Abin; Braumuller, Brian; Prendergast, Conor; Liou, Connie; Deng, Aileen; Roa, Tina; Yeh, Randy; Girard, Antoine; Salvatore, Mary M.; Capaccione, Kathleen M.

doi:10.3390/jcm12134537

Cited by 7 publications

(6 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, the predictive performance of our multivariate model was outstanding, not only across the entire cohort but also in high-risk subgroups, such as Her-2 overexpressing and triple-negative breast cancers [9,12,15,32].…”

Section: Discussionmentioning

confidence: 97%

“…Secondly, the utilization of FDG-PET/CT for staging, primarily at stage IIB, aligned with international recommendations for breast cancer staging [6,[8][9][10][11][12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

“…Hence, FDG-PET/CT has been recommended in numerous studies recently published for staging from stage IIB onwards (depending on the histological subtype) and for assessing treatment response. Additionally, it may contribute significantly to cases of suspected tumor recurrence [6,[8][9][10][11][12][13][14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

Kudura,

Ritz,

Templeton

et al. 2023

Cancers

View full text Add to dashboard Cite

Objectives: We aimed to develop a novel non-linear statistical model integrating primary tumor features on baseline [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), molecular subtype, and clinical data for treatment benefit prediction in women with newly diagnosed breast cancer using innovative statistical techniques, as opposed to conventional methodological approaches. Methods: In this single-center retrospective study, we conducted a comprehensive assessment of women newly diagnosed with breast cancer who had undergone a FDG-PET/CT scan for staging prior to treatment. Primary tumor (PT) volume, maximum and mean standardized uptake value (SUVmax and SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured on PET/CT. Clinical data including clinical staging (TNM) but also PT anatomical site, histology, receptor status, proliferation index, and molecular subtype were obtained from the medical records. Overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) were assessed as endpoints. A logistic generalized additive model was chosen as the statistical approach to assess the impact of all listed variables on CB. Results: 70 women with newly diagnosed breast cancer (mean age 63.3 ± 15.4 years) were included. The most common location of breast cancer was the upper outer quadrant (40.0%) in the left breast (52.9%). An invasive ductal adenocarcinoma (88.6%) with a high tumor proliferation index (mean ki-67 expression 35.1 ± 24.5%) and molecular subtype B (51.4%) was by far the most detected breast tumor. Most PTs displayed on hybrid imaging a greater volume (12.8 ± 30.4 cm3) with hypermetabolism (mean ± SD of PT maximum SUVmax, SUVmean, MTV, and TLG, respectively: 8.1 ± 7.2, 4.9 ± 4.4, 12.7 ± 30.4, and 47.4 ± 80.2). Higher PT volume (p < 0.01), SUVmax (p = 0.04), SUVmean (p = 0.03), and MTV (<0.01) significantly compromised CB. A considerable majority of patients survived throughout this period (92.8%), while five women died (7.2%). In fact, the OS was 31.7 ± 14.2 months and PFS was 30.2 ± 14.1 months. A multivariate prediction model for CB with excellent accuracy could be developed using age, body mass index (BMI), T, M, PT TLG, and PT volume as predictive parameters. PT volume and PT TLG demonstrated a significant influence on CB in lower ranges; however, beyond a specific cutoff value (respectively, 29.52 cm3 for PT volume and 161.95 cm3 for PT TLG), their impact on CB only reached negligible levels. Ultimately, the absence of distant metastasis M displayed a strong positive impact on CB far ahead of the tumor size T (standardized average estimate 0.88 vs. 0.4). Conclusions: Our results emphasized the pivotal role played by FDG-PET/CT prior to treatment in forecasting treatment outcomes in women newly diagnosed with breast cancer. Nevertheless, careful consideration is required when selecting the methodological approach, as our innovative statistical techniques unveiled non-linear influences of predictive biomarkers on treatment benefit, highlighting also the importance of early breast cancer diagnosis.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Secondly, the utilization of FDG-PET/CT for staging, primarily at stage IIB, aligned with international recommendations for breast cancer staging [6,[8][9][10][11][12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

Kudura,

Ritz,

Templeton

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…We have to keep in mind, however, that [ 18 F]PSMA-1007 PET/CT will probably not substitute [ 18 F]FDG PET/CT in the diagnosis of TNBC. First of all, [ 18 F]FDG shows satisfactory diagnostic accuracy [24][25][26]. Secondly, [ 18 F]FDG is widely available and cheaper than 68 Ga-or 18 F-labeled PSMA ligands.…”

Section: Discussionmentioning

confidence: 99%

Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer

Andryszak,

Świniuch,

Wójcik

et al. 2024

Cancers

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (TNBC) exhibits high aggressiveness and a notably poorer prognosis at advanced stages. Nuclear medicine offers new possibilities, not only for diagnosis but also potentially promising therapeutic strategies. This prospective study explores the potential of prostate-specific membrane antigen (PSMA) as a diagnostic and therapeutic target in TNBC. Methods: the research investigates PSMA expression in vivo among TNBC patients using [18F]PSMA-1007 PET/CT and compares it head-to-head with the standard-of-care [18F]FDG PET/CT. Results: The study involves 10 TNBC patients, revealing comparable uptake of [18F]PSMA-1007 and [18F]FDG in primary and metastatic lesions. Nodal metastases were found in eight patients, showing similar SUVmax values in both modalities. Two patients had uncountable lung metastases positive in both [18F]FDG and [18F]PSMA-1007 scans. PET-positive bone metastases were identified by 18F-PSMA in four patients, while elevated [18F]FDG uptake was found only in three of them. Distant metastases displayed higher SUVmax values in the [18F]PSMA-1007 PET/CT, as compared to [18F]FDG. Additionally, brain metastases were exclusively detected using [18F]PSMA-1007. Conclusions: the findings provide valuable insights into the expression of PSMA in TNBC and underscore the potential clinical significance of [18F]PSMA-1007 PET/CT in enhancing both diagnostic and therapeutic approaches for this aggressive breast cancer subtype.

show abstract

“…Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG-PET/CT) has also been used in the diagnosis and staging of TNBC (Ulaner et al 2016 ; Yue et al 2015 ). However, for mastitis, this imaging technique may lead to false-positive results (de Jong et al 2023 ). Therefore, a method for the effective early diagnosis and screening of TNBC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Small animal PET imaging with the 68Ga-labeled pH (low) insertion peptide-like peptide YJL-4 in a triple-negative breast cancer mouse model

Chen,

Song,

Sun

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background The aim of this study was to prepare a novel 68Ga-labeled pH (low) insertion peptide (pHLIP)-like peptide, YJL-4, and determine its value for the early diagnosis of triple-negative breast cancer (TNBC) via in vivo imaging of tumor-bearing nude mice. The novel peptide YJL-4 was designed using a template-assisted method and synthesized by solid-phase peptide synthesis. After modification with the chelator 1,4,7‑triazacyclononane-N,N′,N″-triacetic acid (NOTA), the peptide was labeled with 68Ga. Then, the biodistribution of 68Ga-YJL-4 in tumor-bearing nude mice was investigated, and the mice were imaged by small animal positron emission tomography (PET). Results The radiochemical yield and radiochemical purity of 68Ga-YJL-4 were 89.5 ± 0.16% and 97.95 ± 0.06%, respectively. The biodistribution of 68Ga-YJL-4 in tumors (5.94 ± 1.27% ID/g, 6.72 ± 1.69% ID/g and 4.54 ± 0.58% ID/g at 1, 2 and 4 h after injection, respectively) was significantly greater than that of the control peptide in tumors at the corresponding time points (P < 0.01). Of the measured off-target organs, 68Ga-YJL-4 was highly distributed in the liver and blood. The small animal PET imaging results were consistent with the biodistribution results. The tumors were visualized by PET at 2 and 4 h after the injection of 68Ga-YJL-4. No tumors were observed in the control group. Conclusions The novel pHLIP family peptide YJL-4 can adopt an α-helical structure for easy insertion into the cell membrane in an acidic environment. 68Ga-YJL-4 was produced in high radiochemical yield with good stability and can target TNBC tissue. Moreover, the strong concentration of radioactive 68Ga-YJL-4 in the abdomen does not hinder the imaging of early TNBC.

show abstract

Advances in PET/CT Imaging for Breast Cancer

Cited by 7 publications

References 210 publications

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data

Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer

Small animal PET imaging with the 68Ga-labeled pH (low) insertion peptide-like peptide YJL-4 in a triple-negative breast cancer mouse model

Contact Info

Product

Resources

About